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ABSTRACT 
 
 
OBJECTIVE: The objective of this selective EBM review is to determine “Is prophylactic 
oxybutynin safe and effective in reducing the severity of palmar hyperhidrosis in adults?”  
 
STUDY DESIGN: This review is based on two randomized controlled trials (RCTs) and one 
non-randomized crossover study published in 2008, 2011, and 2012. The studies compared the 
safety and efficacy of oxybutynin in reducing the severity of palmar hyperhidrosis.   
 
DATA SOURCES: All articles used were published in English, in peer-reviewed journals, and 
found using PubMed, Ebscohost, and Cochrane Review databases.   
 
OUTCOMES MEASURED: For all studies, the safety and effectiveness of oxybutynin on 
palmer hyperhidrosis was evaluated using post-treatment clinical questionnaires. For one study, 
symptom improvement was quantitatively measured using Transepidermal Water Loss (TEWL) 
measurements pre- and post-treatment.  
 
RESULTS: Van Houte et al. (2008) found no statistical significance (p > 0.05) in effectiveness 
of sweat inhibition with oxybutynin at doses of 7.5 mg and 15 mg per day. Conversely, the 
Wolosker et al. studies (2011, 2012) saw statistically significant improvement (>80% of 
participants) in palmar hyperhidrosis symptoms (sudoresis) with the administration of 
oxybutynin at doses of 10 mg per day. None of the studies reported worsening symptoms with 
treatment. Noted side effects primarily included dry mouth, in which moderate to severe cases 
were reported in 34.8%-48.1% of participants. Despite the prevalence of dry mouth, it was not 
found to be an impeding factor in the use of oxybutynin for palmar hyperhidrosis.   
 
CONCLUSIONS: Results of two of the three studies demonstrate that 10 mg of daily 
oxybutynin is safe and effective in the prophylactic management of palmar hyperhidrosis in 
those diagnosed with generalized hyperhidrosis (GH). Further comparative studies are warranted 
to investigate whether the long-term use of oxybutynin results in continued symptom 
improvement or tachyphylaxis.   
 
KEY WORDS: Hyperhidrosis, oxybutynin, anticholinergic 
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INTRODUCTION 
Hyperhidrosis is a somatic disorder of hyperactive sweat glands.1,2,3  Individuals with 
hyperhidrosis possess an autonomic neuronal dysfunction which causes the production of more 
sweat than what is needed to maintain thermoregulation.1 This dysfunction most often occurs in 
areas with high concentrations of sweat-producing eccrine glands, most notably the axillae, 
soles, and palms.4 When not due to another disorder (e.g. endocrine dysfunction, cardiovascular 
disease, menopause, etc.), hyperhidrosis is known as primary hyperhidrosis (PH).1,2,3 
Acetylcholine is the main neurotransmitter involved in sympathetic-induced sweat secretion;4 
therefore, anticholinergic therapy is a logical choice when approaching symptomatic 
management of PH. Although surgical sympathectomy is the most definitive treatment, 
complications have lead patients and providers to seek less invasive treatment modalities.1,2,3 
This paper evaluates two randomized controlled studies and a non-randomized crossover study, 
looking at the safety and efficacy of prophylactic oxybutynin, an oral anticholinergic medication, 
for improving symptoms of palmar hyperhidrosis. 
The impact of PH on healthcare resources and costs has yet to be determined; however, it 
should not be ignored. In the United States, PH affects approximately 3% of adults---roughly 7.8 
million Americans.5 The majority prevalence of those with PH are aged 25 to 64 years old, with 
reported age of onset younger than 25 years old.5 Due to the unpredictable and embarrassing 
nature of the disorder, many psychosocial problems develop as a consequence of hyperhidrosis. 
It is documented that those with PH have a lower quality of life as they suffer occupational, 
emotional, psychological, social, and physical impairment.2,3,5  It is estimated that only 38% of 
those with PH discuss their disorder with a healthcare provider. Due to this fact, an exact number 
of healthcare visits per year allocated to PH remains unknown.5 Furthermore, the total  
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healthcare cost of PH has not yet been identified. However, in accordance with this literature 
review, generic oxybutynin costs approximately $636-$954 per year, assuming self-pay pricing.6 
The specific etiology of PH is unknown, but there are believed to be emotional factors as 
well as hereditary factors.2,3 Emotions, such as anxiety, excitement, fear, or anger, are often 
responsible for the exacerbation of hyperhidrosis symptoms.1,2,3 When triggered, the 
hypothalamus sends nerve impulses through pre- and postganglionic sympathetic nerves to sweat 
glands.1,4 Acetylcholine is the primary neurotransmitter responsible for inducing and amplifying 
sweat secretion during neuronal synapse.4 Hyperfunctioning of this sympathetic mechanism 
results in hyperhidrosis. Additionally, an abnormality of chromosome 14q has been linked to 
autosomal dominant inheritance of PH in some families.7  
PH is most commonly diagnosed on history and physical examination8; however, an 
iodine and starch test can be done to test severity, foci of sweating, and response to treatments. 
Diagnosis requires a minimum of six months of sudoresis without a secondary cause, 1,2,3,8 as 
well as at least two of the following: impairs daily activities, has a bilateral and relatively 
symmetric pattern occurring at least once weekly, age of onset younger than 25, cessation of 
focal sweating during sleep, or positive family history of PH.8 There is currently no definitive 
cure for PH, so treatment focuses on minimizing symptoms and improving quality of life.  
Current treatments for palmar hyperhidrosis include tap-water iontophoresis, Botulinum 
toxin type A (Botox), anticholinergic medications, and endoscopic thoracic sympathectomy 
(ETS).9 Tap-water iontophoresis is the use of an electrical current through water to submerged 
hands in order to suppress sweat gland activity. Restrictions include limited efficacy and adverse 
reactions, such as skin cracking and blistering. Botox injections are being used for palmar 
hyperhidrosis and require regular treatments; however, may cause localized temporary weakness  
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and intense pain. ETS surgery is recommended for severe palmar cases and is effective by 
shutting down neuronal impulses to sweat glands; however, many patients experience 
compensatory hyperhidrosis after ETS surgery.2 Although not routinely used, anticholinergic 
medications are being considered as they have been found to decrease sudoresis in patients 
treated for micturition disorders.2,3,9 These medications will be evaluated in this literature review. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not prophylactic 
oxybutynin is safe and effective in reducing the severity of palmar hyperhidrosis in adults. 
METHODS 
Two double blind, randomized controlled trials, and one non-randomized crossover study 
were included in this systematic review. Studies were selected based on various criteria including 
populations studied, interventions used, comparisons made, and outcomes measured. In all three 
included studies, the populations being measured consisted of healthy adults aged 18 and older. 
Van Houte et al.1 included healthy men and women aged 18 to 50, whereas Wolosker et al.2 
included healthy men and women aged 18 to 56 years old, and Wolosker et al.3 included healthy 
men and women aged 18 and older. Additional inclusion criteria in the Wolosker et al. studies 
was a diagnosis of PH, which included palmar hyperhidrosis symptoms. 
For all reviewed studies, the intervention applied was oral administration of oxybutynin. 
Van Houte et al.1 performed two randomized, double-blind crossover studies in which 
participants received  2.5 mg oxybutynin TID (or placebo) for the first study, followed by 5 mg 
oxybutynin TID (or placebo) for the second study performed after a 7 day washout period. For 
both studies, oxybutynin was administered the day prior to testing with an additional dose the 
morning of testing. Both Wolosker et al.2.3 studies administered oxybutynin for 6-12 weeks at  
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incrementally increased doses, beginning with 2.5 mg QD, increasing to BID, then 5 mg BID. 
All three studies compared the effects of oxybutynin to placebo (or no therapeutic treatment) on 
symptom improvement. However, in the van Houte et al.1 study, additional crossover 
comparisons were made between dosages (2.5 mg TID versus 5 mg TID).  
Articles were researched via PubMed, Ebscohost, Cochrane Review databases and were 
selected based on relevance to the clinical question and that measured outcomes included patient 
oriented evidence that matters (POEMS). Key words entered in the PubMed search included 
“hyperhidrosis,” “oxybutynin,” and “anticholinergic.” All three of the selected studies were peer-
reviewed journal articles written in the English language published between 2008 and 2012.  
The studies included in this systematic review were selected based on the following 
inclusion criteria: all were primary research studies (randomized controlled trials, cohort studies, 
crossover studies, etc.), all were published after 1998, all included relevant POEMs, and all 
evaluated efficacy of oxybutynin on palmar hyperhidrosis as one of the measured outcomes. 
Exclusion criteria included studies involving those under 18 years of age, those with secondary 
hyperhidrosis, and those whose hyperhidrosis was not palmar. Specific exclusion criteria varied 
slightly between studies but generally included patients whose past medical history revealed 
diseases where anticholinergic therapy was contraindicated, or diseases where anticholinergic 
therapy is a known treatment (e.g. micturition disorders). Statistics reported in the van Houte et 
al.1 study included t-tests, means, standard deviations in Transepidermal Water Loss (TEWL) 
delta values, whereas the Wolosker et al.2,3 studies included NNT (Wolosker et al.3 only), t-tests, 
p-values, and mean change from baseline. See Table 1 below for Demographics and 
Characteristics of Included Studies. 
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Table 1: Demographics and Characteristics of Included Studies 
Study Type 
# 
Pts 
Age 
(yr) 
Inclusion 
criteria 
Exclusion  
Criteria 
W/D Intervention 
vanHoute1 
(2008) 
RCT 8 20-
46 
Adults aged 
18-50 years 
old 
 
Subjects without: 
urinary obstruction, 
prostate hypertrophy, 
hiatal hernia, other GI 
disorder, myasthenia 
gravis, hyper- or 
hypotension, renal 
failure, liver failure, 
glaucoma, hyper- 
thyroidism, heart 
disease (any); must 
be a non-smoker, not 
pregnant, and not use 
any medication that 
might interact with 
oxybutynin 
0 Therapeutic 
oxybutynin 
2.5 mg TID 
OR 
Therapeutic 
oxybutynin 5 
mg TID 
 
Wolosker2 
(2011) 
Cross
-over  
 
180 18-
56 
Adults aged 
18-56 w/ a 
complaint of 
palmar 
hyperhidro-
sis who may 
also have 
presented w/ 
hyperhidro-
sis on other 
body sites  
Subjects without: 
glaucoma or any 
micturition disorder 
 
41 Therapeutic 
oxybutynin x 
12 wks with 
incrementally 
increased 
doses: 
- 2.5 mg QD 
HS initially 
- 2.5 mg BID 
days 8-42 
- 5 mg BID 
days 43-84 
Wolosker3
(2012) 
RCT 
 
50 18-
50 
Adults aged 
≥18 with a 
complaint of 
palmar or 
axillary 
hyperhidro-
sis with 
intention of 
using oxy-
butynin 
after being 
informed of 
risks and 
benefits  
Subjects without: 
glaucoma, narrow-
angle glaucoma, 
urinary retention, 
gastric retention, 
demonstrated 
hypersensitivity to 
the drug substance or 
other components of 
the drug 
5 Therapeutic 
oxybutynin x 
6 wks with 
incrementally 
increased 
doses: 
- 2.5 mg QD 
HS initially 
- 2.5 mg BID 
days 8-21 
- 5 mg BID 
days 22-42  
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OUTCOMES MEASURED 
All three studies measured palmar hyperhidrosis symptom improvement as well as side 
effects via post-treatment questionnaires completed by study participants. In van Houte et al.1, 
participants’ subjective impression of sweat inhibition was scored by a 100-mm visual analogue 
scale. Side effects were measured using a Likert scale, ranked 1-4, with “1” being low impact 
and “4” being extreme severe impact. Both Wolosker et al.2,3 studies used clinical questionnaires 
that addressed improvement in hyperhidrosis symptoms and severity of dry mouth (a known 
anticholinergic medication side effect) using scoring on a Likert scale. Symptom improvement 
was scored as “null,” “slight improvement,” “moderate improvement,” or “great improvement.” 
Severity of dry mouth was scored on a range from absence of side effect to severe side effect.  
 Additionally, the van Houte et al.1 study used Transepidermal Water Loss (TEWL) 
measurements to evaluate quantitative improvements in sweating. A double-probe Tewameter 
(TM 300, Courage+Khazaka Cologne, Germany) was used to measure the degree of sweating on 
the central part of the left palm before and after exercise-induced sweating. Participants’ 
sweating threshold was documented using a cycle ergometer, initially started at a level of 60W, 
then increased every 3 minutes by 30W until sweating occurred. Exercise was continued for an 
additional 6 minutes at the sweating threshold rate. TEWL measurements were taken before 
exercise and after the 6 minutes for each study in the crossover. Differences between pre- and 
post-exercise measurements were compared for each study and TEWL-delta values determined.1 
RESULTS 
All three studies were performed using the methods previously outlined. In van Houte et 
al.1, 8 healthy adult participants (4 male, 4 female), were randomly assigned to double-blind 
crossover studies. No participants were lost to follow-up. In Wolosker et al.2, 180 healthy adult  
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participants (85 male, 95 female), were administered oxybutynin at incrementally increasing 
doses, then followed prospectively for 12 consecutive weeks. Of the 180 participants, 41 were 
lost to follow-up. In Wolosker et al.3, 50 healthy adult participants (unknown gender 
distribution), were randomly assigned to a double-blind study where they were administered 
oxybutynin (or placebo) at incrementally increasing doses, then followed prospectively for 6 
consecutive weeks. Of the initial 50 participants, 5 were lost to follow-up (3 from placebo group, 
2 from oxybutynin group). 
Efficacy of Oxybutynin 
In van Houte et al.1, the degree of palmar sweating following oxybutynin administration 
was measured using the TEWL-delta value, which is the difference between pre-exercise TEWL 
measurements and TEWL measurements taken at the completion of the exercise test. Means and 
standard deviation of TEWL-delta values were given, and comparisons of values were done 
using two-sided paired t-tests; however, t-test values were not given. For both the 2.5 mg and 5 
mg groups, the p-value was > 0.05 (exact value not specified), meaning neither treatment group 
had statistically significant results (Table 2). Conversely, in the 2.5 mg group, one out of the 
eight participants reported suppression of sweating in their impression of sweat inhibition 
evaluation. In the 5 mg group, no sweating suppression was reported. 
Table 2: TEWL-delta values at oxybutynin dosages of 2.5 mg and 5 mg (van Houte et al.1) 
TEWL-delta (g/m2 per hr) Oxybutynin 2.5 mg Placebo Oxybutynin 5 mg Placebo 
Palm Mean 30.6 35.4 28.8 23.3 
 Standard Deviation 10.09 14.72 12.21 10.93 
 
In Wolosker et al.2, improvement in symptoms of palmar hyperhidrosis was assessed 
using clinical questionnaires administered before treatment and after treatment completion. Of 
the 139 participants who completed the study, questionnaire data showed that nearly 90%  
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experienced improvement in palmar hyperhidrosis symptoms, with 54.5% of those having 
experienced “great” symptom improvement (Table 3).  
Table 3: Evolution of hyperhidrosis with the use of oxybutynin (Wolosker et al.2) 
Site Improvement n (%) 
Null Slight Moderate Great Total 
Palm 16 (11.5) 8 (5.7) 48 (34.5) 67 (48.2) 139 
 
Similarly, the Wolosker et al.3 study evaluated efficacy of oxybutynin on palmar 
hyperhidrosis via clinical questionnaires on symptom severity. Over 80% of participants in the 
treatment group experienced “moderate” or “great” symptoms improvement, with the majority 
being “great” improvement (47.8%). Of all participants with any improvement, 26% (n=6) were 
from the placebo group and only reported “moderate” improvement. Comparisons between the 
two groups were statistically significant (P < 0.001). Tables 4 and 5 summarize the results and 
efficacy of the Wolosker et al.3 study. The ABI shows an increase in treatment effect with the 
oxybutynin group compared to the placebo group. The RBI represents the effectiveness of 
oxybutynin and the relative probability of experiencing symptom improvement with oxybutynin 
treatment compared to placebo. The NNT is calculated to determine the number of patients that 
need to receive oxybutynin in order to benefit one patient with symptom improvement. In 
Wolosker et al.3, only three patients need treated to have one with symptom improvement. 
   
Table 4: Evolution ion of hyperhidrosis with the use of oxybutynin (Wolosker et al.3) 
Evolution Placebo No. (%) Oxybutynin No. (%) P-value 
Worse (0.0) 0 (0.0) <.001 
Null/slight 16 (72.7) 6 (26.1)  
Moderate 6 (27.3) 6 (26.1)  
Great 0 (0.0) 11 (47.8)  
Total 22 (100) 23 (100)  
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Table 5: Efficacy of oxybutynin on hyperhidrosis symptom improvement: NNT 
Proportion of 
patients having 
symptom 
improvement on 
placebo  
(CER) 
Proportion of 
patients having 
symptom 
improvement on 
oxybutynin 
(EER) 
Relative benefit 
increase  
(RBI) 
Absolute 
benefit increase  
(ABI) 
Number needed 
to treat (NNT) 
EER- CER 
CER 
EER - CER 1/ABI 
0.27 0.74 1.74 0.47 3 
 
Safety of Oxybutynin 
Known side effects of anticholinergic medication include diarrhea, dizziness, dry eyes, 
and dry mouth. Other side effects which were not seen in any of the reviewed studies include 
mydriasis, flushing, and rash.1,2,3,6   
In the van Houte et al.1 study, of the participants who received 2.5 mg TID, 50% (n=2) 
reported adverse side effects, which included mild diarrhea and dizziness. Of the participants 
who received 5 mg TID, 37.5% (n=3) participants reported dry mouth and dry eyes which were 
moderate (n=2) or severe (n=1). No side effects were reported for the control group.  
In the Wolosker et al.2 study, headache (n=5), mild urinary retention (n=4), and dry 
mouth (n=98) were the only reported side effects at dosages of 10 mg oxybutynin QD, with dry 
mouth being the most reported side effect (70.5%). Dry mouth cases were further broke down to 
mild (22.3%), moderate (19.4%), or severe (28.7%). No other side effects were mentioned.  
In Wolosker et al.3, dry mouth was the only noted side effect. Following administration of 10 mg 
oxybutynin QD (or placebo), moderate to severe dry mouth was reported in 34.8% of the 
treatment group and 9.1% of the control group (p-value of 0.038). Despite the prevalence of dry 
mouth, it was not an impeding factor in the use of oxybutynin as >50% of those from the 
treatment group in Wolosker et al.3 continued using oxybutynin after study completion.   
 Table 6 delineates the NNH for experiencing dry mouth as an adverse side effect to  
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treatment. For the studies being evaluated, the NNH indicated that for every 2-4 patients given 
oxybutynin for hyperhidrosis, one patient will develop moderate to severe dry mouth. 
Table 6: Efficacy of oxybutynin on development of adverse events: NNH 
 
DISCUSSION 
Only the Wolosker et al. studies found statistical significance in the improvement of 
palmar hyperhidrosis with the use of prophylactic oxybutynin. This is perhaps because the van 
Houte et al. study used only normohidrotic participants whereas the Wolosker et al. studies used 
participants diagnosed with PH. The suspected pathologic difference in sympathetic outflow may 
provide a challenge when making comparisons between normohidrotic and hyperhidrotic 
individuals. Also, van Houte et al. measured severity of sweating after inducing exercise whereas 
the Wolosker et al. studies examined severity of spontaneous sweating as seen in PH. Although 
van Houte et al. was able to quantitatively measure the severity of palmar sweating, the results 
are not statistically significant for all the factors aforementioned.    
The prevalence of anticholinergic side effects, specifically dry mouth, seemed somewhat 
inhibitory for continued use of oxybutynin; however, none of the studies lost participants due to 
adverse reactions. Furthermore, >50% of those from the treatment group in Wolosker et al.3 
electively continued using oxybutynin after study completion. This would infer that the 
perceived benefit of taking oxybutynin exceeding that of the perceived risk of dry mouth.  
 Proportion of 
patients having 
mod-severe dry 
mouth on 
placebo  
(CER) 
Proportion of 
patients having 
mod-severe dry 
mouth on 
oxybutynin 
(EER) 
Relative 
risk 
increase  
(RRI) 
Absolute 
risk 
increase  
(ARI) 
Number 
needed to 
harm 
(NNH) 
EER- CER 
CER 
EER - 
CER 
1/ARI 
van Houte et al.1 0 0.38 0 0.38 3 
Wolosker et al.2 0 0.63 0 0.63 2 
Wolosker et al.3 0.09 0.35 2.89 0.26 4 
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Major limitations of all three studies included small sample size and a short study 
duration. Specifically, van Houte et al. had a significantly shorter intervention period of 2 days 
compared to the others of 6 and 12 weeks. Longer studies would provide data on the long-term 
efficacy and side effect profile of oxybutynin on palmar hyperhidrosis. Given that there is a 
known compensatory hyperhidrosis with sympathectomy surgery, it would be valuable to know 
if this same complication is seen with long-term use of anticholinergic medications. Despite 
dropout rates of 22% in Wolosker et al.2 and 10% in Wolosker et al.3, results remained 
significant after an intention to treat analysis was applied.  
 
CONCLUSION 
Based on this systematic review, it can be concluded that there is improvement of palmar 
hyperhidrosis symptoms with 10 mg daily prophylactic oral oxybutynin. The greatest 
improvement in symptoms, seen in >80% of participants, was seen in those diagnosed with PH 
(Wolosker et al. studies) as there was no statistically significant improvement seen in the van 
Houte et al. study using normohidrotic individuals. The most burdensome side effect experienced 
in all studies included dry mouth; however, side effects were not severe enough for participants 
to abandon the study. Additionally, future studies are warranted to evaluate the long-term effects 
of prophylactic anticholinergic medications on hyperhidrosis symptom improvement as well as 
anticholinergic side effects as there is a concern for tachyphylaxis with continued use. Future 
studies should consider the addition of an objective means of measuring palmar hyperhidrosis, 
such as the TEWL or an iodine and starch test; however, given that hyperhidrosis is not life-
threating and results are measured in the patient’s perception of symptom improvement, 
subjective measurements may be sufficient to determine the efficacy of oxybutynin for palmar 
hyperhidrosis. 
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